The Apex Times
Above the Noise
Business Wire
BusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex Times
Back to front
Moderna shares jump after late-stage data for personalized mRNA melanoma vaccine with Merck’s Keytruda
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 11:26 AM EDT

Moderna shares jump after late-stage data for personalized mRNA melanoma vaccine with Merck’s Keytruda

Moderna and Merck & Co said their personalized mRNA cancer vaccine, intismeran, when combined with Keytruda, slowed melanoma recurrence and spread in a late-stage trial, sending Moderna shares higher.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna’s shares rose sharply after the company and its partner, Merck & Co, said a personalized mRNA cancer vaccine called intismeran showed positive results in a late-stage study when used with Merck’s immunotherapy Keytruda.

According to the report carried by Proactive Investors, the companies said the combination slowed melanoma recurrence and reduced disease spread, a set of outcomes that investors typically treat as a key announcement of clinical benefit in oncology trials.

Intismeran is described in the report as a personalized mRNA cancer vaccine, meaning it is tailored to an individual patient’s tumor-related targets rather than being a one-size-fits-all shot. Moderna has positioned this approach as a way to train the immune system against cancers by using mRNA instructions specific to a patient’s disease.

The companies’ announcement also highlighted the pairing with Keytruda. Keytruda, Merck’s anti-PD-1 therapy, is designed to help the immune system recognize and attack tumors. In combination strategies, sponsors often aim to use an immunotherapy to “release the brakes” on immune responses while a vaccine component helps direct those responses toward cancer-related targets.

The report said the trial results related specifically to melanoma, a skin cancer where recurrence and metastatic spread are major drivers of patient outcomes and a frequent focus of late-stage endpoints.

While the headline outcome was described as slowing recurrence and spread, the report did not provide in-line details such as the study’s name, the exact patient population, the time horizon for follow-up, or the magnitude of effect. It also did not specify whether the results met predefined statistical thresholds for primary or secondary endpoints.

For Moderna, the update represents another high-profile checkpoint for its mRNA oncology strategy, which relies on its ability to rapidly generate personalized vaccine designs and deliver them at scale. For Merck, the finding continues a broader push to combine Keytruda with therapies that may improve response durability or prevent relapse.

Investors and clinicians will likely look next for additional disclosures, including full trial reporting on endpoint definitions, safety and tolerability, and how the benefits may vary by subgroup. Without more granular data, it remains difficult to assess the strength and clinical durability of the observed effect.

Why It Matters

  • Oncology investors often treat late-stage results as a gate for whether an asset moves toward larger regulatory and commercialization paths.
  • A demonstrated reduction in melanoma recurrence and spread could support broader interest in personalized mRNA vaccination approaches in solid tumors.
  • Combination evidence with Keytruda is especially relevant because PD-1 immunotherapies are widely used, and durable control remains a central challenge.
  • The lack of detailed endpoint and safety figures in the reported text may limit how much the market can interpret the strength and durability of the benefit, at least initially.

Sources

Key Facts

  • Moderna and Merck announced results from a late-stage trial involving the personalized mRNA cancer vaccine intismeran.
  • The companies reported that intismeran combined with Merck’s Keytruda slowed melanoma recurrence and disease spread.
  • The announcement drove a rise in Moderna shares, according to a market report published on Aug. 19, 2026.
  • The report characterized intismeran as personalized, meaning it is tailored to individual patients’ tumor targets.
  • The market report did not include specific figures, statistical levels, or endpoint-by-endpoint results in the text provided.

Healthcare Related

Moderna shares jump after late-stage data for personalized mRNA melanoma vaccine with Merck’s Keytruda | The Apex Times